VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2022 | Clinical characteristics of patients achieving seizure freedom with adjunctive cenobamate

Christian Brandt, MD, Bielefeld University, Medical School, Bielefeld, Germany, discusses an open-label extension of the Phase II C017 trial (NCT01866111) of adjunctive cenobamate that evaluated the clinical characteristics of patients achieving seizure freedom for at least one continuous year. The clinical characteristics investigated included demographic factors such as age and gender, as well as the duration of epilepsy and previously failed antiepileptic drug regimens. No significant differences were found between the characteristics of patients that became seizure-free and those who did not. Importantly, around 20% of patients who failed at least five antiseizure medications became seizure-free for at least one year. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.

Disclosures

Honoraria for speaking or consulting activities from Angelini/Arvelle, Eisai, Equilibre, GW Pharmaceuticals, Johnson&Johnson, Marinus, UCB Pharma, Xenon and Zogenix